Cohen's SAC Capital Boosts Stake in United Therapeutics (UTHR) to 7.4%
More News related to UTHR
- United Therapeutics Corporation (UTHR) Chairman and Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell
- Quarterly Changes to the NASDAQ Q-50 Index
- Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
- Morning Movers 5/26: MAPP, CYTK, CMM, EMIS, UTHR Higher; SHLO, GM, CSIG, FSLR Lower
- FDA Approves United Therapeutics (UTHR) ADCIRCA Tablets for the Treatment of Pulmonary Arterial Hypertension
In a 13G filing on United Therapeutics Corp. (Nasdaq: UTHR), Steven Cohen's SAC Capital disclosed a 7.4% stake (1,680,100 shares) in the company. The firm held 372,500 shares in United Therapeutics at the quarter ended June 30, 2008.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases.
SAC is a $14 billion multi-strategy, hedge fund founded by Steven A. Cohen in 1992.
Related Categories
13GsStocks Mentioned
-1.26Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
